Affymax News

OSAKA, Japan & PALO ALTO, Calif.-- --Aug 28, 2008 - Takeda Pharmaceutical Company Limited and Affymax, Inc.

Affymax Inc. and its Japanese partner Takeda Pharmaceutical Co. Ltd. have ceased development of Hematide, a synthetic pegylated peptide-based erythropoiesis-stimulating agent , as a product to treat ...

Affymax Inc. and Takeda Pharmaceutical Company Ltd. said Thursday they agreed to suspend co-development of Hematide for treatment of chemotherapy-induced anemia and instead focus all development efforts for the ...

Aug 7, 2008 - Affymax, Inc. today announced that the independent Data Monitoring Committee , which provides oversight for the Phase 3 program for Hematide , has completed its first review of the data and ...

Main Category: Urology / Nephrology Also Included In: Clinical Trials / Drug Trials Article Date: 14 Jul 2008 Affymax, Inc.

Posted Jul 2nd 2008 11:37AM by Eric Buscemi Filed under: Analyst reports , Analyst initiations MOST NOTEWORTHY: Telefonica, Affymax and Hatteras Financial were today's noteworthy initiations: Deutsche Bank ...

A live webcast of the presentations will be available on the investors section of the company ' s website at www.affymax.com . A replay will also be available for 30 days following the presentations. via Earth Times

Affymax, Inc. and Takeda Global Research & Development today announced data from their ongoing Phase 2 trial to assess the long-term safety and tolerability of Hematide , a potential treatment of anemia. via Earth Times

Drug company Affymax Inc. reported higher revenue for 2007, and a decline in its loss. via Bizjournals